Journal Watch · Nature Communications · 2026

Ultrasensitive detection of lung inflammation in male mice using immuno-magnetic particle imaging.

Overall, immuno-MPI provides a non-invasive approach that avoids ionizing radiation and supports pulmonary inflammation monitoring.

Pedron S, Martinez de Lizarrondo S, D'Arco L et al.Nature Communications3 min readPharma relevance 50/100

DOI: 10.1038/s41467-026-75724-zPMID: 42642371Study type: preclinical (animal / model) study

TL;DR

Overall, immuno-MPI provides a non-invasive approach that avoids ionizing radiation and supports pulmonary inflammation monitoring.

Key findings

  • Specificity for VCAM-1 is confirmed by the absence of signal using control antibodies (MPIO@IgG) and competitive blocking with free αVCAM-1 antibodies.
  • Overall, immuno-MPI provides a non-invasive approach that avoids ionizing radiation and supports pulmonary inflammation monitoring.

What they did

Here, we present immuno-Magnetic Particle Imaging (immuno-MPI) using micron-sized iron oxide particles targeted to VCAM-1, a key marker of endothelial inflammation. In three lung inflammation models in male mice, MPIO@αVCAM-1 generates high-contrast images within 3 minutes following intravenous injection at 1 mg/kg, with rapid accumulation at the inflamed endothelium and fast clearance of unbound particles. Predominantly confined to the vasculature, these particles selectively target VCAM-1 and discriminate inflamed from healthy lungs at doses as low as 0.18 mg/kg (7.5 µg iron).

Full abstract (original)

Background: Timely and sensitive detection of inflammatory and infectious lung diseases remains a major clinical challenge. Current diagnostic approaches often identify pathology only at advanced stages, leaving gaps in acute triage, fibrotic activity assessment, transplant rejection monitoring and inflammation follow-up. Magnetic Particle Imaging (MPI) offers a sensitive, background-free, whole-body imaging modality without ionizing radiation.

What they did: Here, we present immuno-Magnetic Particle Imaging (immuno-MPI) using micron-sized iron oxide particles targeted to VCAM-1, a key marker of endothelial inflammation. In three lung inflammation models in male mice, MPIO@αVCAM-1 generates high-contrast images within 3 minutes following intravenous injection at 1 mg/kg, with rapid accumulation at the inflamed endothelium and fast clearance of unbound particles. Predominantly confined to the vasculature, these particles selectively target VCAM-1 and discriminate inflamed from healthy lungs at doses as low as 0.18 mg/kg (7.5 µg iron).

Results & conclusions: Specificity for VCAM-1 is confirmed by the absence of signal using control antibodies (MPIO@IgG) and competitive blocking with free αVCAM-1 antibodies. Overall, immuno-MPI provides a non-invasive approach that avoids ionizing radiation and supports pulmonary inflammation monitoring.

Abstract © the authors / Nature Communications (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1038/s41467-026-75724-z · PubMed 42642371.

Why it matters for pharma & biotech

  • Relevant to General & Medicine teams tracking Nature Communications for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Nature Communications study find?

Overall, immuno-MPI provides a non-invasive approach that avoids ionizing radiation and supports pulmonary inflammation monitoring.

What type of study is this?

It is a preclinical (animal / model) study, published in Nature Communications in 2026. Here, we present immuno-Magnetic Particle Imaging (immuno-MPI) using micron-sized iron oxide particles targeted to VCAM-1, a key marker of endothelial inflammation.

Where can I read the original paper?

The original is at the publisher via DOI 10.1038/s41467-026-75724-z. PubMed ID: 42642371. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Pedron S, Martinez de Lizarrondo S, D'Arco L et al.. Ultrasensitive detection of lung inflammation in male mice using immuno-magnetic particle imaging.. Nature Communications (2026). DOI: 10.1038/s41467-026-75724-z.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/ultrasensitive-detection-of-lung-inflammation-in-male-mice-using-immuno-75724z/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides